2. Academic Validation
  3. Revisiting the Role of Eotaxin-1/CCL11 in Psychiatric Disorders

Revisiting the Role of Eotaxin-1/CCL11 in Psychiatric Disorders

  • Front Psychiatry. 2018 Jun 14;9:241. doi: 10.3389/fpsyt.2018.00241.
Antonio L Teixeira 1 2,  Clarissa S Gama 3,  Natalia P Rocha 1 2,  Mauro M Teixeira 1
Affiliations

Affiliations

  • 1 Neuropsychiatry Program & Immuno-Psychiatry Lab, Department of Psychiatry & Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, United States.
  • 2 Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
  • 3 Molecular Psychiatry Laboratory, Hospital de Clínicas de Porto Alegre, Programa de Pós-Graduação em Psiquiatria e Ciências do Comportamento, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
PMID: 29962972 DOI: 10.3389/fpsyt.2018.00241
Abstract

Eotaxin-1/CCL11 is a chemokine originally implicated in the selective recruitment of eosinophils into inflammatory sites during allergic reactions, being thoroughly investigated in asthma, allergic rhinitis, and other eosinophil-related conditions. Eotaxin-1/CCL11 is also involved with a skewed immune response toward a type-2 (Th2) profile. In addition to its role in immune response, recent studies have shown that eotaxin-1/CCL11 is associated with aging, neurogenesis and neurodegeneration, being able to influence neural progenitor cells, and microglia. Increased circulating levels of eotaxin-1/CCL11 have been described in major psychiatric disorders (schizophrenia, bipolar disorder, major depression), sometimes correlating with the severity of psychopathological and cognitive parameters. As similar findings have been reported in neurodegenerative conditions such as Alzheimer's disease, it has been hypothesized that mechanisms involving eotaxin-1/CCL11 signaling may underlie the "accelerated aging" profile commonly linked to psychiatric disorders. Future studies must determine whether eotaxin-1/CCL11 can be regarded as a prognostic biomarker and/or as therapeutic target for resistant/progressive cases.

Keywords

Alzheimer's disease; CCL11; Eotaxin-1; aging; bipolar disorder; depression; schizophrenia.

Figures
Products